The monthly prophylactic injection reduces bleeds by interfering with the production of specific proteins for both types of hemophilia with or without inhibitors.
FRIDAY, March 31, 2023 (HealthDay News) An experimental injectable drug appears effective in reducing bleeds in patients with hemophilia A and B, according to a pair of new clinical
Trials of fitusiran, found it stopped bleeds in up to two-thirds (66 per cent) of patients with haemophillia A or B. Experts say the preventative treatment could soon improve patients daily lives